12/23
04:05 pm
vrtx
Vertex to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 13
Low
Report
Vertex to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 13
12/23
03:19 pm
vrtx
Vertex Secures FDA Approval for New Cystic Fibrosis Drug Alyftrek [Yahoo! Finance]
Low
Report
Vertex Secures FDA Approval for New Cystic Fibrosis Drug Alyftrek [Yahoo! Finance]
12/23
10:31 am
vrtx
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) had its price target raised by analysts at Scotiabank from $426.00 to $430.00. They now have a "sector perform" rating on the stock.
Low
Report
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) had its price target raised by analysts at Scotiabank from $426.00 to $430.00. They now have a "sector perform" rating on the stock.
12/23
10:31 am
vrtx
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) had its price target lowered by analysts at Truist Financial Co. from $550.00 to $460.00. They now have a "buy" rating on the stock.
Low
Report
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) had its price target lowered by analysts at Truist Financial Co. from $550.00 to $460.00. They now have a "buy" rating on the stock.
12/23
09:08 am
vrtx
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) had its price target lowered by analysts at JPMorgan Chase & Co. from $503.00 to $500.00. They now have an "overweight" rating on the stock.
Low
Report
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) had its price target lowered by analysts at JPMorgan Chase & Co. from $503.00 to $500.00. They now have an "overweight" rating on the stock.
12/23
07:45 am
vrtx
Lost Money on Vertex Pharmaceuticals Incorporated (VRTX)? You May Have Been Affected by Fraud - Contact Levi & Korsinsky
Low
Report
Lost Money on Vertex Pharmaceuticals Incorporated (VRTX)? You May Have Been Affected by Fraud - Contact Levi & Korsinsky
12/20
03:46 pm
vrtx
Vertex Announces US FDA Approval of ALYFTREK™, a Once-Daily Next-in-Class CFTR Modulator for the Treatment of Cystic Fibrosis
Low
Report
Vertex Announces US FDA Approval of ALYFTREK™, a Once-Daily Next-in-Class CFTR Modulator for the Treatment of Cystic Fibrosis
12/20
03:35 pm
vrtx
Vertex Announces U.S. FDA Approval for TRIKAFTA (elexacaftor/tezacaftor/ivacaftor and ivacaftor) to Include Additional Non-F508del TRIKAFTA-Responsive Variants
Neutral
Report
Vertex Announces U.S. FDA Approval for TRIKAFTA (elexacaftor/tezacaftor/ivacaftor and ivacaftor) to Include Additional Non-F508del TRIKAFTA-Responsive Variants
12/20
03:00 pm
vrtx
Vertex Pharmaceuticals Incorporated Investigated Regarding Potential Securities Law Violations - Contact Levi & Korsinsky for Details - VRTX
Low
Report
Vertex Pharmaceuticals Incorporated Investigated Regarding Potential Securities Law Violations - Contact Levi & Korsinsky for Details - VRTX
12/20
03:00 pm
vrtx
Shareholders that lost money on Vertex Pharmaceuticals Incorporated (VRTX) should contact Levi & Korsinsky about Securities Fraud Investigation - VRTX
Low
Report
Shareholders that lost money on Vertex Pharmaceuticals Incorporated (VRTX) should contact Levi & Korsinsky about Securities Fraud Investigation - VRTX
12/20
01:18 pm
vrtx
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) had its price target lowered by analysts at Barclays PLC from $509.00 to $418.00. They now have an "equal weight" rating on the stock.
Low
Report
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) had its price target lowered by analysts at Barclays PLC from $509.00 to $418.00. They now have an "equal weight" rating on the stock.
12/20
11:58 am
vrtx
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) had its price target lowered by analysts at BMO Capital Markets from $566.00 to $520.00. They now have an "outperform" rating on the stock.
Low
Report
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) had its price target lowered by analysts at BMO Capital Markets from $566.00 to $520.00. They now have an "outperform" rating on the stock.
12/20
09:01 am
vrtx
Channel Therapeutics Highlights Differences Between NaV1.7 and NaV1.8 in Light of Recent Clinical Data on Suzetrigine [Yahoo! Finance]
Low
Report
Channel Therapeutics Highlights Differences Between NaV1.7 and NaV1.8 in Light of Recent Clinical Data on Suzetrigine [Yahoo! Finance]
12/20
08:45 am
vrtx
Vertex Pharmaceuticals Inc. (VRTX) Investors Who Have Lost Money Should Contact Block & Leviton to Find Out How They Might Recover Money Through The Firm's Investigation
Low
Report
Vertex Pharmaceuticals Inc. (VRTX) Investors Who Have Lost Money Should Contact Block & Leviton to Find Out How They Might Recover Money Through The Firm's Investigation
12/20
08:19 am
vrtx
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) had its price target lowered by analysts at HC Wainwright from $600.00 to $535.00. They now have a "buy" rating on the stock.
Low
Report
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) had its price target lowered by analysts at HC Wainwright from $600.00 to $535.00. They now have a "buy" rating on the stock.
12/20
08:19 am
vrtx
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) had its "hold" rating re-affirmed by analysts at Needham & Company LLC.
Low
Report
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) had its "hold" rating re-affirmed by analysts at Needham & Company LLC.
12/19
05:38 pm
vrtx
A Success Story: Digital Opinion Leader Analysis for Cystic Fibrosis Treatments | DelveInsight [Yahoo! Finance]
Low
Report
A Success Story: Digital Opinion Leader Analysis for Cystic Fibrosis Treatments | DelveInsight [Yahoo! Finance]
12/19
02:29 pm
vrtx
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) was downgraded by analysts at Oppenheimer Holdings Inc. from an "outperform" rating to a "market perform" rating.
Low
Report
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) was downgraded by analysts at Oppenheimer Holdings Inc. from an "outperform" rating to a "market perform" rating.
12/19
02:02 pm
vrtx
Dow tries to rebound from longest losing streak since 1974 [USA TODAY]
Low
Report
Dow tries to rebound from longest losing streak since 1974 [USA TODAY]
12/19
01:10 pm
vrtx
Why Is Vertex Pharmaceuticals Stock Trading Lower On Thursday After Back Pain Trial Data? [Yahoo! Finance]
Low
Report
Why Is Vertex Pharmaceuticals Stock Trading Lower On Thursday After Back Pain Trial Data? [Yahoo! Finance]
12/19
12:57 pm
vrtx
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) had its price target lowered by analysts at Bank of America Co. from $545.00 to $522.00. They now have a "buy" rating on the stock.
Low
Report
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) had its price target lowered by analysts at Bank of America Co. from $545.00 to $522.00. They now have a "buy" rating on the stock.
12/19
12:57 pm
vrtx
Vertex's stock hurt after non-opioid pain drug shows benefit similar to placebo [Yahoo! Finance]
Low
Report
Vertex's stock hurt after non-opioid pain drug shows benefit similar to placebo [Yahoo! Finance]
12/19
11:13 am
vrtx
Vertex Pharmaceuticals Stock Dives After Mixed Drug Study Results [Yahoo! Finance]
Low
Report
Vertex Pharmaceuticals Stock Dives After Mixed Drug Study Results [Yahoo! Finance]
12/19
10:50 am
vrtx
Vertex Pharmaceuticals Inc. (VRTX) Investigated For Securities Fraud; Block & Leviton Encourages Investors Who Have Lost Money to Contact the Firm
Low
Report
Vertex Pharmaceuticals Inc. (VRTX) Investigated For Securities Fraud; Block & Leviton Encourages Investors Who Have Lost Money to Contact the Firm
12/19
10:41 am
vrtx
Vertex's $10 Billion Blow: Painkiller Trial Results Spark Investor Panic [Yahoo! Finance]
Low
Report
Vertex's $10 Billion Blow: Painkiller Trial Results Spark Investor Panic [Yahoo! Finance]